News

It will join targeted Pulse Electro Magnetic Field therapy (tPEMF) and closed-loop Transcranial Electrical Stimulation (cl-TES) as one of Rio Grande Neurosciences’ core technologies. Despite undergoing treatment with

The investment will accelerate Science 37’s development and rollout of its new operating model, which solves some of the greatest inefficiencies in conducting clinical trials. Science 37 co-founder

The partnership will seek to apply Riverside Research’s patented, quantitative, tissue-characterization algorithms to the ExactVu™ high-resolution micro-ultrasound platform to develop new capabilities in the system’s ability to detect

The summit aims to address the vital role of scientific research in the improvement and sustainable development of the African population health, with specific emphasis on how to

The facility, which is expected to start operations in 2017, will manufacture about 40 million packs and 850 million tablets of around 30 medicines every year. It represents

The company expects to complete the study in the second half of 2016. It is a multi-center, single-arm, open-label trial in healthy women at least 18 years old

Inotuzumab ozogamicin is an investigational antibody-drug conjugate (ADC), which features a monoclonal antibody (mAb) targeting CD22,9 cell surface antigen expressed on about 90% of B-cell malignancies,10 linked to

The trial, which will also include study sites in Europe and Australia, is designed to identify whether the company’s pancreatic cancer treatment (Cell-in-a-Box capsules + low-doses ifosfamide chemotherapy)

This phase IIa study is a randomized, open-label, three-arm study of AL-335, a nucleotide-based HCV NS5B polymerase inhibitor, odalasvir, an HCV NS5A inhibitor and simeprevir, an HCV NS3/4A